United States Hemostatic Sealants in Arterial Surgery Market - Size, Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

United States Hemostatic Sealants in Arterial Surgery Market Overview

The United States Hemostatic Sealants in Arterial Surgery market reached a value of approximately USD 156.17 Million in 2025. The market is expanding steadily, driven by increasing volumes of vascular and cardiovascular procedures, rising prevalence of arterial disorders, and growing preference for advanced surgical hemostatic technologies. Healthcare providers are increasingly adopting fibrin-based, synthetic, and combination sealants to improve intraoperative bleeding control, reduce complications, and enhance surgical outcomes. Continuous product innovation, favorable reimbursement for vascular interventions, and increasing adoption of minimally invasive arterial procedures are further supporting market development across hospitals and specialized surgical centers.

United States Hemostatic Sealants in Arterial Surgery Market Growth Analysis and Key Influencers

United States Hemostatic Sealants in Arterial Surgery Market Dynamics

This section analyzes factors influencing the market, including growth drivers, restraints, opportunities, technological advancements, regulatory developments, product innovations, reimbursement trends, and evolving clinical practices shaping adoption across arterial surgical procedures.

United States Hemostatic Sealants in Arterial Surgery Market Growth Drivers

Increasing FDA Arterial Closure Approval Boosting the Market Growth Prospects

Rising catheter-based arterial procedures and demand for faster recovery are supporting market growth in the United States. For instance, in June 2026, FDA approved CyndRx’s AbsorbaSeal vascular closure device for femoral arterial access-site closure after diagnostic or interventional catheterization procedures. This approval is expected to support the use of advanced bleeding-control solutions, reduce time to hemostasis and ambulation, and strengthen product uptake across vascular surgery and interventional care settings during the forecast period.

United States Hemostatic Sealants in Arterial Surgery Market Restraints

Safety Label Updates Restrain the United States Hemostatic Sealants Market Adoption

Strict application requirements and concerns over product performance remain key market restraints for hemostatic sealants used in arterial procedures. For instance, in August 2025, FDA approved a TachoSil labeling update adding non-adherence as a warning and adverse reaction, along with stronger instructions for correct handling and application. This may increase training needs, slow rapid product switching, and keep hospitals cautious when selecting advanced sealant products for cardiovascular and arterial surgery during the forecast period.

United States Hemostatic Sealants in Arterial Surgery Market Opportunities

Rising Aortic Surgery Approval to Boost the Market Landscape

Growing aortic repair volumes and demand for improved surgical outcomes are creating market opportunities for sealant suppliers in the United States. For instance, in June 2026, Artivion received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis for acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion. Wider access to complex aortic repair technologies is expected to increase hospital focus on adjunct bleeding-control tools used in high-risk arterial procedures.

United States Hemostatic Sealants in Arterial Surgery Market Trends

Room Temperature Hemostats are Likely to Propel the Market Expansion

Preference for easier storage, faster operating-room readiness, and lower preparation burden is shaping market trends in surgical hemostasis. For instance, in May 2025, Baxter launched Hemopatch Sealing Hemostat as a room-temperature collagen pad approved for hemostasis and sealing in open and minimally invasive surgeries. This development is expected to push manufacturers toward user-friendly products with longer shelf life, simpler handling, and broader use across surgical departments during the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

United States Hemostatic Sealants in Arterial Surgery Market Share

Fibrin-Based Sealants Expected to Dominate the Market Segment by Product Type

Fibrin-based sealants are likely to dominate the product type segment, having held approximately 46% market share in the historical period. Their proven effectiveness in achieving rapid hemostasis, excellent tissue compatibility, and widespread utilization during complex vascular procedures continue to support strong clinical preference. Increasing demand for reliable biologic sealants in arterial reconstruction and cardiovascular interventions further reinforces their adoption across healthcare facilities. These factors strengthen the position of market within evolving vascular surgery practices.

Leading Players in the United States Hemostatic Sealants in Arterial Surgery Market

United States Hemostatic Sealants in Arterial Surgery Market Segmentation

Key Questions Answered in the United States Hemostatic Sealants in Arterial Surgery Market Report

• What was the United States hemostatic sealants in arterial surgery market value in 2025?
• What is the United States hemostatic sealants in arterial surgery market forecast outlook for 2026-2035?
• What major factors aid the demand for the United States hemostatic sealants in arterial surgery market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major United States hemostatic sealants in arterial surgery market trends?
• Which product type segment is expected to dominate the market?
• Which surgical application segment is expected to hold the largest market share?
• Which disease indication is expected to account for the highest market share?
• Which end user is expected to account for the highest market share?
• Who are the key players in the United States hemostatic sealants in arterial surgery market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with vascular surgeons, cardiovascular specialists, hospital procurement professionals, medical device manufacturers, surgical technology experts, regulatory consultants, and healthcare industry executives involved in arterial surgery and hemostatic sealant adoption across the United States.
• Secondary Research: Sources included U.S. FDA publications and PMA databases, official company press releases, corporate announcements, investor communications, peer-reviewed vascular surgery literature, government publications, and reputable medical device and healthcare news sources.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.